SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 139 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,113,146 | -1.8% | 76,663 | +42.8% | 0.00% | -100.0% |
| Q2 2023 | $1,133,764 | 0.0% | 53,682 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,133,764 | -23.3% | 53,682 | -7.6% | 0.00% | 0.0% |
| Q4 2022 | $1,478,519 | -99.9% | 58,095 | +34.2% | 0.00% | 0.0% |
| Q3 2022 | $1,040,571,000 | +16.9% | 43,303 | -6.4% | 0.00% | – |
| Q2 2022 | $889,984,000 | +31.7% | 46,257 | +19.0% | 0.00% | – |
| Q1 2022 | $675,595,000 | -20.6% | 38,872 | 0.0% | 0.00% | – |
| Q4 2021 | $850,908,000 | +14.5% | 38,872 | 0.0% | 0.00% | – |
| Q3 2021 | $742,844,000 | +1.4% | 38,872 | -8.9% | 0.00% | – |
| Q2 2021 | $732,678,000 | -14.6% | 42,672 | +11.2% | 0.00% | – |
| Q1 2021 | $858,333,000 | +47.3% | 38,387 | +46.5% | 0.00% | – |
| Q4 2020 | $582,688,000 | – | 26,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |